← Leaderboards
Hiroyuki Nakai
Oregon Health & Science University
$9,286,279
Attributed
$13,618,266
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2005–24$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,618,266 · 8
By mechanism
R01$6,711,999 · 3
UC4$3,604,708 · 1
U01$2,893,272 · 1
R21$295,818 · 1
R56$111,375 · 1
P41$1,094 · 1
Top collaborators
- Markus Grompe5 shared
- Mark A Kay5 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Bert Brandon Boyer$11,963,441
- Charles T Roberts$5,489,068
Others in their field
Top investigators on “Gene Therapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$164,199,916
- Gregory H Reaman · National Childhood Cancer Foundation$155,841,493
- Randall J Bateman · Washington University$122,781,098
- Eric Martin McDade · Washington University$94,632,845
- Ronald G Crystal · Weill Medical College Of Cornell Univ$82,649,124
- Robert B. Diasio · University Of Alabama At Birmingham$73,470,685
Research focus
Gene TherapyVectorVirusCellsAdeno-Associated Viral VectorDependovirusBaseIn VivoBiologySerotypingStructureVirus Host InteractionTechnologyCapsidSiteGene DeliveryMediatingPrimatesProteinsDoseDirected Molecular EvolutionClinical ApplicationGenomeCellular Biology
Grant awards (24)
Mechanistic Studies of AAP and Capsid Assembly of AAV Vectors$692,751
R01 · FY2024 · AI · contact PI
Mechanistic Studies of AAP and Capsid Assembly of AAV Vectors$717,237
R01 · FY2023 · AI · contact PI
Mechanistic Studies of AAP and Capsid Assembly of AAV Vectors$729,095
R01 · FY2022 · AI · contact PI
Gene Therapy for Diabetes$699,431
U01 · FY2022 · DK · contact PI
Mechanistic Studies of AAP and Capsid Assembly of AAV Vectors$745,597
R01 · FY2021 · AI · contact PI
Gene Therapy for Diabetes$720,877
U01 · FY2021 · DK · contact PI
Mechanistic Studies of AAP and Capsid Assembly of AAV Vectors$761,323
R01 · FY2020 · AI · contact PI
Gene Therapy for Diabetes$729,093
U01 · FY2020 · DK · contact PI
Gene Therapy for Diabetes$743,871
U01 · FY2019 · DK · contact PI
AAV capsid functions, immune evasion and neuronal targeting in mice and NHP$336,875
R01 · FY2018 · NS · contact PI
AAV capsid functions, immune evasion and neuronal targeting in mice and NHP$336,875
R01 · FY2017 · NS · contact PI
AAV capsid functions, immune evasion and neuronal targeting in mice and NHP$336,875
R01 · FY2016 · NS · contact PI
AAV capsid functions, immune evasion and neuronal targeting in mice and NHP$336,875
R01 · FY2015 · NS · contact PI
In vivo targeting of diabetes-relevant human cell types with rAAV vectors$3,604,708
UC4 · FY2014 · DK
AAV capsid functions, immune evasion and neuronal targeting in mice and NHP$336,875
R01 · FY2014 · NS · contact PI
Vector and Host Cellular Biology in AAV Vector Transduction in Vivo$279,231
R01 · FY2012 · DK · contact PI
Vector and Host Cellular Biology in AAV Vector Transduction in Vivo$279,231
R01 · FY2011 · DK · contact PI
PROCESSING VIRUS BARCODES$1,094
P41 · FY2011 · RR · contact PI
Vector and Host Cellular Biology in AAV Vector Transduction in Vivo$274,941
R01 · FY2010 · DK · contact PI
Vector and Host Cellular Biology in AAV Vector Transduction in Vivo$275,565
R01 · FY2009 · DK · contact PI
Vector and Host Cellular Biology in AAV Vector Transduction in Vivo$272,653
R01 · FY2008 · DK · contact PI
Vector and host cellular biology in AAV vector transduction in vivo$111,375
R56 · FY2007 · DK · contact PI
Establishment of the Risk of AAV Vector Integration$146,803
R21 · FY2005 · DK
Establishment of the Risk of AAV Vector Integration$149,015
R21 · FY2004 · DK